European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases

Información del proyecto

EU-RESPONSE

Identificador del acuerdo de subvención: 101015736

DOI

10.3030/101015736

Fecha de la firma de la CE 3 Septiembre 2020

Fecha de inicio 1 Julio 2020

Fecha de finalización 30 Junio 2026

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total

€ 16 055 304,10

Aportación de la UE

€ 15 719 450,00

Coordinado por

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France

CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.

Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .

Resultado final

Demonstrators, pilots, prototypes (1)

Project website

project website and Internal communication tools

Publicaciones

Other (15)

Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: lessons learnt and challenges from the EU DisCoVeRy clinical trial

Autores: Diallo A and DisCoVeRy Study Group
Publicado en: 2023
Editor: Pharmacol Res Perspect
DOI: 10.1002/prp2.1072

Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group

Autores: EU-Response investigators group; Alpha Diallo; Marius Trøseid; Victoria Charlotte Simensen; Anaïs Boston; Jacques Demotes; Inge Christoffer Olsen; Florence Chung; José Artur Paiva ; Maya Hites ; Florence Ader ; Jose Ramon Arribas ; Andreas Baratt-Due ; Øyvind Melien ; Evelina Tacconelli ; Thèrèse Staub ; Richard Greil ; Sotirios Tsiodras ; Matthias Briel ; Hélène Esperou ; France Mentré ;
Publicado en: Clinical Microbiology and Infection, 2021
Editor: Elsevier
DOI: 10.1016/j.cmi.2021.10.011

Ensuring quality control in a clinical trial during the COVID-19 pandemic: the experience of the Inserm C20-15 DisCoVeRy study

Autores: Fougerou-Leurent C, Delmas C, Saillard J, Dumousseaux M, Ferrane A et Al.
Publicado en: 2023
Editor: Contemp Clin Trials
DOI: 10.1016/j.cct.2023.107267

Effects of Jak Inhibitors in Adults Hospitalized Due to Covid-19: A Systematic Review and Individual Participant Data Meta-Analysis of Randomized Clinical Trials

Autores: Alain Amstutz, Stefan Schandelmaier, Hannah Ewald, Benjamin Speich, Johannes M. Schwenke, Christof Schönenberger, Stephan Schobinger, Thomas Agoritsas, Kay M. Tomashek, Seema U. Nayak, Mat Makowski, Alejandro Morales-Ortega, David Bernal-Bello, Giovanni Pomponio, Alessia Ferrarini, Monireh Ghazaeian, Frances Hall, Simon Bond, María Teresa García-Morales, María Jiménez-González, José R. Arri
Publicado en: The Lancet (SSRN), 2024
Editor: preprint

Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials

Autores: Amstutz A, Speich B, Mentré F, Rueegg CS, Belhadi D, Assoumou L, Burdet C, Murthy S, Dodd LE, Wang Y, Tikkinen KAO, Ader F, Hites M et al
Publicado en: 2023
Editor: Lancet Respir Med
DOI: 10.1016/s2213-2600(22)00528-8

Assessing the evidence on remdesivir

Autores: Troseid M, Hites M, Barrat-Due, Ader F, Yazdanpanah Y
Publicado en: The Lancet Infectious Diseases, 2021, Página(s) 1630-31
Editor: Elsevier
DOI: 10.1016/s1473-3099(21)00695-2

Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19

Autores: Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Mentré F, Burdet C ; DisCoVeRy Study Group
Publicado en: 2022
Editor: Lancet Infect Dis
DOI: 10.1016/s1473-3099(22)00295-x

Experiences and challenges with the new European Clinical Trials Regulation

Autores: Patrick-Brown TD , Bourner J , Kali S , Trøseid M , Yazdanpanah Y , Olliaro P , Olsen IC
Publicado en: 2023
Editor: BMC/Springer Nature
DOI: 10.21203/rs.3.rs-2514582/v1

Implementation of a Centralised Pharmacovigilance System in Academic Pan-European Clinical Trials: Experience from EU-Response and Conect4Children Consortia

Autores: Terzic V et DisCoVeRy Study Group
Publicado en: 2023
Editor: Br J Clin Pharmacol
DOI: 10.1111/bcp.15669

Immunocompromised patients have been neglected in COVID-19 trials: a call for action

Autores: Marius Trøseid; Maxime Hentzien; Florence Ader; Sandra Wagner Cardoso; Jose R. Arribas; Jean-Michel Molina; Nicolas Mueller; Maya Hites; Fabrice Bonnet; Oriol Manuel; Dominique Costagliola; Beatriz Grinsztejn; Inge Christoffer Olsen; Yazdan Yazdapanah; Alexandra Calmy
Publicado en: European Society of Clinical Microbiology and Infectious Diseases, 2022
Editor: Elsevier
DOI: 10.1016/j.cmi.2022.05.005

Modeling remdesivir antiviral efficacy in COVID-19 hospitalized patients of the randomized, controlled, open-label DisCoVeRy trial

Autores: Guillaume Lingas, Nadège Néant, Alexandre Gaymard, Drifa Belhadi, Gilles Peytavin, Maya Hites, Thérèse Staub , Richard Greil, Jose-Artur Paiva, Julien Poissy, Nathan Peiffer-Smadja, Dominique Costagliola, Yazdan Yazdanpanah, Florent Wallet, Amandine Gagneux-Brunon, France Mentré, Florence Ader Charles Burdet, Jérémie Guedj, Maude Bouscambert-Duchamp and the DisCoVeRy study group
Publicado en: MEDRXIV, 2021
Editor: medRxiv
DOI: 10.1101/2021.10.19.21265209;t

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

Autores: Trøseid M, Arribas JR, Assoumou L, Holten AR, Poissy J, Terzić V, Mazzaferri F, Baño JR, Eustace J, Hites M, Joannidis M, Paiva JA, Reuter J, Püntmann I, Patrick-Brown TDJH, Westerheim E, Nezvalova-Henriksen K, Beniguel L, Dahl TB, Bouscambert M, Halanova M, Péterfi Z, Tsiodras S, Rezek M, Briel M, Ünal S, Schlegel M, Ader F, Lacombe K, Amdal CD, Rodrigues S, Tonby K, Gaudet A, Heggelund L,
Publicado en: 2023
Editor: BMC
DOI: 10.1186/s13054-022-04205-8

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-B--1a and hydroxychloroquine in hospitalized patients with COVID-19

Autores: Florence Ader 1, Nathan Peiffer-Smadja 2, Julien Poissy 3, Maude Bouscambert-Duchamp 4, Drifa Belhadi 5, Alpha Diallo 6, Christelle Delmas 7, Juliette Saillard 7, Aline Dechanet 8, Noémie Mercier 6, Axelle Dupont 9, Toni Alfaiate 9, François-Xavier Lescure 10, François Raffi 11, François Goehringer 12, Antoine Kimmoun 13, Stéphane Jaureguiberry 14, Jean Reign
Publicado en: Clinical Microbiology and Infection, 2021
Editor: Elsevier
DOI: 10.1016/j.cmi.2021;05.020

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.

Autores: Florence Ader, Prof, MD,a,b,* Maude Bouscambert-Duchamp, PharmD,c Maya Hites, Prof, MD,d Nathan Peiffer-Smadja, MD,e,f,g Julien Poissy, Prof, MD,h,i Drifa Belhadi, MSc,e,j Alpha Diallo, MD,k Minh-Patrick Lê, PharmD,l,m Gilles Peytavin, PharmD,e,l Thérèse Staub, Prof, MD,n Richard Greil, Prof, MD,o,p,q Jérémie Guedj, PhD,e Jose-Artur Paiva, Prof, MD,r,s Dominique Costagliola, PhD,
Publicado en: 2021
Editor: Elsevier
DOI: 10.1016/s1473-3099(21)00485-0

Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults

Autores: Florence Ader corresponding author and Discovery French Trial Management Team
Publicado en: 2020
Editor: BMJ Open
DOI: 10.1136/bmjopen-2020-041437

Peer reviewed articles (7)

Coordination of COVID-19 platform trials in Europe

Autores: Jacques Demotes, Victoria Charlotte Simensen, Keiko Ueda, Sareema Javaid, Paula Garcia, Burç Aydin, John-Arne Røttingen
Publicado en: Trials, Edición 25, 2024, ISSN 1745-6215
Editor: BioMed Central
DOI: 10.1186/s13063-024-08126-5

Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial

Autores: Vida Terzić, Joe Miantezila Basilua, Nicolas Billard, Lucie de Gastines, Drifa Belhadi, Claire Fougerou-Leurent, Nathan Peiffer-Smadja, Noémie Mercier, Christelle Delmas, Assia Ferrane, Aline Dechanet, Julien Poissy, Hélène Espérou, Florence Ader, Maya Hites, Claire Andrejak, Richard Greil, José-Artur Paiva, Thérèse Staub, Evelina Tacconelli, Charles Burdet, Dominique Costagliola, France M
Publicado en: Clinical Infectious Diseases, Edición 79, 2024, Página(s) 382-391, ISSN 1058-4838
Editor: University of Chicago Press
DOI: 10.1093/cid/ciae170

Association between SARS‐CoV‐2 viral kinetics and clinical score evolution in hospitalized patients

Autores: Nadège Néant, Guillaume Lingas, Alexandre Gaymard, Drifa Belhadi, Maya Hites, Thérèse Staub, Richard Greil, Jose‐Artur Paiva, Julien Poissy, Nathan Peiffer‐Smadja, Dominique Costagliola, Yazdan Yazdanpanah, Maude Bouscambert‐Duchamp, Amandine Gagneux‐Brunon, Florence Ader, France Mentré, Florent Wallet, Charles Burdet, Jérémie Guedj, null null
Publicado en: CPT: Pharmacometrics & Systems Pharmacology, Edición 12, 2023, Página(s) 2027-2037, ISSN 2163-8306
Editor: Nature Publishing Group
DOI: 10.1002/psp4.13051

Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results

Autores: WHO Solidarity Trial Consortium; Hongchao Pan 1, Richard Peto 1, Ana-Maria Henao-Restrepo 1, Marie-Pierre Preziosi 1, Vasee Sathiyamoorthy 1, Quarraisha Abdool Karim 1, Marissa M Alejandria 1, César Hernández García 1, Marie-Paule Kieny 1, Reza Malekzadeh 1, Srinivas Murthy 1, K Srinath Reddy 1, Mirta Roses Periago 1, Pierre Abi Hanna 1, Florence Ader 1, Abdullah
Publicado en: The new england journal o f medicine, 2021, ISSN 0028-4793
Editor: Massachusetts Medical Society
DOI: 10.1056/nejmoa2023184

Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial

Autores: Hans-Kittil Viermyr, Kristian Tonby, Erica Ponzi, Sophie Trouillet-Assant, Julien Poissy, José R. Arribas, Virginie Dyon-Tafani, Maude Bouscambert-Duchamp, Lambert Assoumou, Bente Halvorsen, Nuriye Basdag Tekin, Alpha Diallo, Lucie De Gastines, Ludvig A. Munthe, Sarah Louise Murphy, Thor Ueland, Annika E. Michelsen, Fridtjof Lund-Johansen, Pål Aukrust, Joy Mootien, Benjamin Dervieux, Yoann Zerbi
Publicado en: eBioMedicine, Edición 111, 2025, Página(s) 105511, ISSN 2352-3964
Editor: Elsevier BV
DOI: 10.1016/j.ebiom.2024.105511

Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial

Autores: Maya Hites, Clément R. Massonnaud, Eva Larranaga Lapique, Drifa Belhadi, Simon Jamard, François Goehringer, François Danion, Jean Reignier, Nathalie de Castro, Denis Garot, Karine Lacombe, Violaine Tolsma, Emmanuel Faure, Denis Malvy, Thérèse Staub, Johan Courjon, France Cazenave-Roblot, Anne Ma Dyrhol Riise, Paul Leturnier, Guillaume Martin-Blondel, Claire Roger, Karolina Akinosoglou, Vincen
Publicado en: Journal of Infection, Edición 88, 2024, Página(s) 106120, ISSN 0163-4453
Editor: W. B. Saunders Co., Ltd.
DOI: 10.1016/j.jinf.2024.106120

Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial

Autores: Guillaume Lingas; Nadège Néant; Alexandre Gaymard; Drifa Belhadi; Gilles Peytavin; Maya Hites; Thérèse Staub; Richard Greil; Jose-Artur Paiva; Julien Poissy; Nathan Peiffer-Smadja; Dominique Costagliola; Yazdan Yazdanpanah; Florent Wallet; Amandine Gagneux-Brunon; France Mentré; Florence Ader; Charles Burdet; Jérémie Guedj; Maude Bouscambert-Duchamp
Publicado en: Journal of Antimicrobial Chemotherapy, 2022, ISSN 0305-7453
Editor: Oxford University Press
DOI: 10.1093/jac/dkac048